Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 2
1993 3
1994 1
1997 1
1998 1
1999 7
2000 1
2001 2
2002 1
2003 4
2004 2
2005 2
2006 1
2008 2
2009 6
2010 9
2011 6
2012 1
2014 2
2015 1
2017 1
2018 1
2019 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.
Francica BJ, Holtz A, Lopez J, Freund D, Chen A, Wang D, Powell D, Kipper F, Panigrahy D, Dubois RN, Whiting CC, Prasit P, Dubensky TW. Francica BJ, et al. Among authors: prasit p. Cancer Res Commun. 2023 Aug 8;3(8):1486-1500. doi: 10.1158/2767-9764.CRC-23-0249. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37559947 Free PMC article.
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M, Powderly JD, Bastos BR, Karasic TB, Crysler OV, Munster PN, McKean MA, Emens LA, Saenger YM, Ged Y, Stagg R, Smith S, Whiting CC, Moon A, Prasit P, Jenkins Y, Standifer N, Dubensky TW, Whiting SH, Ulahannan SV. Yarchoan M, et al. Among authors: prasit p. Cancer Res Commun. 2024 Apr 18;4(4):1100-1110. doi: 10.1158/2767-9764.CRC-24-0082. Cancer Res Commun. 2024. PMID: 38551394 Free PMC article. Clinical Trial.
A role for oleoylethanolamide in chronic lymphocytic leukemia.
Masoodi M, Lee E, Eiden M, Bahlo A, Shi Y, Ceddia RB, Baccei C, Prasit P, Spaner DE. Masoodi M, et al. Among authors: prasit p. Leukemia. 2014 Jul;28(7):1381-7. doi: 10.1038/leu.2014.10. Epub 2014 Jan 13. Leukemia. 2014. PMID: 24413323
Pyridazinones as selective cyclooxygenase-2 inhibitors.
Li CS, Brideau C, Chan CC, Savoie C, Claveau D, Charleson S, Gordon R, Greig G, Gauthier JY, Lau CK, Riendeau D, Thérien M, Wong E, Prasit P. Li CS, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2003 Feb 24;13(4):597-600. doi: 10.1016/s0960-894x(02)01045-4. Bioorg Med Chem Lett. 2003. PMID: 12639538
Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies.
Jacintho JD, Baccei CS, Bravo Y, Broadhead A, Chen A, Correa L, Fischer K, Laffitte B, Lee C, Lorrain DS, Messmer D, Prasit P, Stebbins KJ, Stock NS. Jacintho JD, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2019 Feb 1;29(3):503-508. doi: 10.1016/j.bmcl.2018.12.045. Epub 2018 Dec 21. Bioorg Med Chem Lett. 2019. PMID: 30594433
Identification of the first potent, selective and bioavailable PPARα antagonist.
Bravo Y, Baccei CS, Broadhead A, Bundey R, Chen A, Clark R, Correa L, Jacintho JD, Lorrain DS, Messmer D, Stebbins K, Prasit P, Stock N. Bravo Y, et al. Among authors: prasit p. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72. doi: 10.1016/j.bmcl.2014.03.090. Epub 2014 Apr 4. Bioorg Med Chem Lett. 2014. PMID: 24745969
5-lipoxygenase-activating protein is an arachidonate binding protein.
Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ. Mancini JA, et al. Among authors: prasit p. FEBS Lett. 1993 Mar 8;318(3):277-81. doi: 10.1016/0014-5793(93)80528-3. FEBS Lett. 1993. PMID: 8440384 Free article.
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist.
Stebbins KJ, Broadhead AR, Cabrera G, Correa LD, Messmer D, Bundey R, Baccei C, Bravo Y, Chen A, Stock NS, Prasit P, Lorrain DS. Stebbins KJ, et al. Among authors: prasit p. Eur J Pharmacol. 2017 Aug 15;809:130-140. doi: 10.1016/j.ejphar.2017.05.008. Epub 2017 May 5. Eur J Pharmacol. 2017. PMID: 28483457
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al. Prasit P, et al. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8. doi: 10.1016/s0960-894x(99)00288-7. Bioorg Med Chem Lett. 1999. PMID: 10406640
56 results